Global Sacroiliitis Treatment Market Overview
Sacroiliitis Treatment Market Size was valued at USD 32.9 Billion in 2022. The sacroiliitis treatment market industry is projected to grow from USD 38.95 Billion in 2023 to USD 150.43 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.40% during the forecast period (2023 - 2032).The market is growing due to several technological advancements in the devices and an increase in the prevalence of joint ailments. The rising incidences and prevalence of joint disorders, rising public awareness of the condition, increased government initiatives and private sector investment in R&D, and an aging population are the key market drivers fostering the growth of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for sacroiliitis treatment is driven by the rising number of people who have arthritis. A few reasons fueling the growth of the market include the rising prevalence of rheumatoid arthritis worldwide, the introduction of novel therapeutic agents, and favorable reimbursement policies for expensive treatment products. The prevalence of rheumatoid arthritis (RA) was calculated to be 0.46 percent in the paper "The prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review" that was published in Rheumatology International in November 2020. The market will grow due to the increased adoption of therapies for treating RA. An increase in diagnosed cases is anticipated as diagnostic capabilities and healthcare facilities in emerging nations improve. The market for sacroiliitis treatment is expected to develop due to this aspect during the forecast period. The aging population is predicted to increase demand for the product, as is patient and healthcare professional awareness of arthritis and ways to prevent it.
Figure 1: Diagnosed and predicted cases of arthritis globally from 2000 to 2040
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The main driver driving the market during the projected period is anticipated to be the rising usage of minimally invasive operations. Additionally, using new technology and improving diagnostic tools for sacroiliac joint problems will probably result in better SI joint fusion systems. Robotic surgery has become increasingly common in several medical device disciplines, including orthopedic devices. Sacroiliac joint fusion procedures can be carried out with more control and precision with the help of robotic equipment. They provide benefits, including tactile feedback, enhanced visualization, and the capacity to carry out complicated movements in confined places, which lessen the procedure's invasiveness and may shorten the recovery period. Furthermore, superior implant designs and materials based on nanotechnology have been created for sacroiliac joint fusion. These implants are created precisely to offer stability, encourage fusion, and enable the best load transfer throughout the joint.
As more cutting-edge materials and technologies are used to develop superior and safer SI joint fusion systems, the market is anticipated to expand throughout the estimated time frame. This covers the usage of 3D-printed titanium implants and additive manufacturing. For instance, Genesys Spine's Siros Lateral Sacroiliac Joint Fusion system uses 3D-printed implants to stabilize best. The self-harvesting iFuse-3D implants by SI-BONE are titanium plasma spray-coated 3D implants that replicate native cancellous bone. These 3D-printed and additively made implants enable a linked, "bone-like" surface that might enhance osteointegration. Thus, driving the sacroiliitis treatment market revenue.
The sacroiliitis treatment market segmentation, based on type, includes medications, joint injections, joint fusion, radiofrequency denervation, and electrical stimulation. The medications segment dominated the market, accounting for 40.2% of market revenue (13.2 Billion). disease prevalence is on the rise, which is accelerating category growth. Medications like NSAIDs and their manufacturers are anticipated to see robust demand and supply over the projected period due to the rise in arthritis incidence. On the other hand, the radiofrequency denervation segment is likely to increase at the quickest rate during the forecasted period. Radiofrequency denervation helps restore daily motion function while providing mild pain relief. The segment is anticipated to develop due to rising levels of knowledge regarding sacroiliac joint discomfort and available treatments, various research projects, and the high incidence of risk factors.
Figure 2: Sacroiliitis Treatment Market, by Type, 2022 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The sacroiliitis treatment market segmentation, based on end-user, includes hospitals, clinics, and others. In 2022, the hospital end-user segment held the biggest market share. Most procedures are now conducted in hospitals, and minimally invasive surgeries are becoming increasingly popular. These are the main drivers driving this segment's rise. Hospitals also offer patients specialized, long-term care. The ASC end-user market is predicted to grow at the quickest rate. The growing number of ASCs is credited with this expansion. In March 2021, there were approximately 187 Medicare-certified ASCs in Washington state, 442 in Texas, 457 in Florida, 817 in California, and 368 in Georgia, according to the Centres for Medicare & Medicaid Services (CMS).
Sacroiliitis Treatment Regional Insights
By region, the report gives market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American sacroiliitis treatment market area will dominate this market. The existence of important actors, a sophisticated healthcare infrastructure, and expanding reimbursement coverage can be credited for the region's high share. The area has a strong healthcare system, a sizable patient base, and a high prevalence of persistent lower back pain, frequently accompanied by sacroiliac joint dysfunction.
Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.
Figure 3: SACROILIITIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe’s sacroiliitis treatment market accounts for the second-largest market share. The area has a strong healthcare system, a sizable patient base, and a high prevalence of persistent lower back pain, frequently accompanied by sacroiliac joint dysfunction. Further, the German sacroiliitis treatment market held the largest market share, and the UK sacroiliitis treatment market was the rapidly-growing market in the European region.
The Asia-Pacific Sacroiliitis Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. The market in this region is influenced by important aspects such as the expanding patient population, the high prevalence of chronic diseases, the building of healthcare infrastructure, and the rising levels of research and development in the biotechnology industry. The existence of significant market participants, including China, India, and Japan, fuels market expansion. Moreover, China’s sacroiliitis treatment market held the largest market share, and the Indian sacroiliitis treatment market was the rapidly-growing market in the Asia-Pacific region.
Sacroiliitis Treatment Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the sacroiliitis treatment market, grow even more. To increase their worldwide footprint, market participants are also engaging in various strategic actions. Important market developments include introducing new products, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sacroiliitis treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the sacroiliitis treatment industry to benefit clients and increase the market sector. In recent years, the sacroiliitis treatment industry has offered some of the most significant advantages to medicine. Major players in the sacroiliitis treatment market, including Smith & Nephew Plc, Ipsen Group, Salix Pharmaceuticals, Johnson & Johnson, Pfizer, and others, are attempting to increase market demand by investing in research and development operations.
PainTEQ is a company that offers interventional pain treatment options for back pain and sacroiliac (SI) fusion. The company offers a SI joint stabilization device that offers SI joint dysfunction sufferers a safe, minimally invasive treatment for pain, assisting patients in eliminating chronic pain. In September 2021, PainTEQ announced the award of three additional U.S. patents specific to the LinQ treatment. The LinQ technique is a revolutionary, minimally invasive procedure developed to aid individuals with SI joint problems. These patents cement PainTEQ's position as an industry leader in minimally invasive therapies for lower back pain related to the SI joint - a frequently misdiagnosed source of back pain that affects up to 30% of all lower back pain sufferers, or more than 10 million Americans each year.
Orthofix Medical Inc. is a medical device firm that provides orthopedic and spine solutions to physicians. spine, which includes bone growth and healing therapies, spinal implants, and regenerative tissue products, and orthopedics, which provides items used in fracture repair, deformity correction, and bone reconstruction operations, are the company's two primary segments. In June 2020, Orthofix Medical Inc. announced the FDA 510(k) clearance and the first patient implants of the FIREBIRDTM SI Fusion System. The FIREBIRD SI Fusion System is the first 3D-printed titanium bone screw launched in the United States to treat SI joint dysfunction. It is designed to compress and stabilize the sacroiliac joint (SI joint) during fusion.
Key Companies in the sacroiliitis treatment market include
Pfizer
Allergan
Ipsen Group
Teva Pharmaceuticals
Novartis
Johnson & Johnson
STEROID S.p.A.
Sanofi
Salix Pharmaceuticals
Zimmer Holdings, Inc.
Smith & Nephew Plc
Others.
Sacroiliitis Treatment Industry Developments
March 2023:CoreLink has announced that the Siber Ti--3D Printed SI Joint Fusion System has received FDA clearance. The Siber Ti System provides a broad range of totally porous, nano-surfaced, 3D-printed implants. CoreLink's patented Mimetic Metal technology is used in these new implants to mimic natural bone with directional lattice architecture and trabecular holes, as well as features at the macro, micro, and nano (MNM) levels.
September 2022:Camber Spine has announced that its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices have received FDA approval. These medicines are intended for use in skeletally mature patients with degenerative disc degeneration at one or two contiguous levels from L2-S1. SPIRA-P and SPIRA-T, like all products in Camber's SPIRA technology platform, have strategically located and optimally sized holes for graft packing.
Medications
Joint Injections
Joint Fusion
Radiofrequency Denervation
Electrical Stimulation
Hospitals
Clinics
Others
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 32.9 Billion |
| Market Size 2023 | USD 38.95 Billion |
| Market Size 2032 | USD 150.43 Billion |
| Compound Annual Growth Rate (CAGR) | 18.40% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered | Type and End-User |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil. |
| Key Companies Profiled | Smith & Nephew Plc, Ipsen Group, Salix Pharmaceuticals, Johnson & Johnson, and Pfizer. |
| Key Market Opportunities | Clinical trial activities |
| Key Market Dynamics | Increasing prevalence of lower back, buttock, groin, and lower extremity pain |
Frequently Asked Questions (FAQ) :
The sacroiliitis treatment market size was valued at USD 32.9 Billion in 2022.
The worldwide market is forecast to expand at a CAGR of 18.40% from 2023 to 2032.
North America had the largest share of the market
The key players in the market are Smith & Nephew Plc, Ipsen Group, Salix Pharmaceuticals, Johnson & Johnson, and Pfizer.
The medication category dominated the market in 2022.
The hospitals had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
